A groundbreaking medical trial has found that providing pluripotent cells to unborn babies diagnosed with spina bifida while undergoing fetal surgery can be a "important advancement" in treating birth defects.
Study Parameters and Security
The American study examined six unborn babies with the 'open' form of spina bifida. Medical teams placed regenerative cells sourced from the maternal placenta directly onto the infant's spine while the defect was being closed.
Importantly, the stem cell application demonstrated a favorable safety profile. Doctors verified that the cells did not cause cancerous growths, interfere with wound healing, or block the correction of co-occurring hindbrain herniation.
Encouraging Results
Imaging conducted after delivery indicated a full resolution of Chiari malformation in each of the babies. This neurological improvement is closely linked to better mobility and function.
"Should it enable more children able to walk who otherwise would not, then it would become the new treatment paradigm," noted the study director. "The outcomes appear super exciting and pave the way for a variety of prospective innovative interventions."
Future Implications and Hope
Experts not involved in the trial proposed that additional validation of these noted improvements could herald a "new era" in fetal surgery. The possibility of ameliorating neural deficits seen in utero is considered a transformative goal.
Notably important would be advancements for bladder and bowel function, which are frequent complications for individuals living with this defect.
The Path Forward
Despite this being a first-in-human effort involved a limited number of patients, its established security and encouraging indicators offer a robust platform for broader investigative efforts. The addition of cellular treatment with established fetal surgery techniques holds considerable promise for transforming outcomes for babies yet to be born with spina bifida.